Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels

Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels: A Randomized, Double-Blind, Placebo-Controlled Three-Arm Trial

This is a randomized, double-blind, placebo-controlled, parallel-group study evaluating the effects of two distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Approximately 180 participants will be randomized to one of three study arms: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, or placebo. Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period. The primary outcome is the change in intracellular NAD⁺ levels, assessed via at-home finger-stick blood collection at baseline and study completion. Secondary endpoints include changes in aging-related symptoms (AMFS scores), health-related quality of life (RAND SF-36), and evaluation of safety and tolerability. All assessments, including electronic questionnaires, are completed remotely without in-person visits.

Study Overview

• Status: Not yet recruiting
• Conditions: NAD; NAD+ Levels in the Blood
• Intervention / Treatment: Dietary supplement: Placebo; Dietary supplement: Qualia NAD⁺ version 1; Dietary supplement: Qualia NAD⁺ version 2

• Study Type: Interventional
• Enrollment (Estimated): 180
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: William Scuba; Phone Number: 855-281-2328; Email: support@qualialife.com

Study Locations

• United States
  • California
    • Carlsbad, California, United States, 92011
      • Qualia Life Sciences
      • Contact: Abhi Ardagh; Phone Number: 855-281-2328; Email: support@qualialife.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

Provide voluntary, written, informed consent to participate in the study Agree to provide a valid cell phone number and are willing to receive communications through text Can read and write English Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly Willing to complete questionnaires, records, and diaries associated with the study.

Healthy male and female participants aged 35-75 years Willing to self-administer the intracellular NAD⁺ finger-stick test at home (baseline and Day 28) Willing to avoid supplements, energy drinks/shots, or other products containing niacin, niacinamide, nicotinamide riboside, or NMN for ≥ 2 weeks before baseline and throughout the study

Exclusion Criteria:

Women who are pregnant, breastfeeding, or planning to become pregnant during the trial Known food intolerances/allergy to any ingredients in the product Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer Having had a significant cardiovascular event in the past 6 months Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines On immunosuppressive therapy Individuals who were deemed incompatible with the test protocol Adults lacking capacity to consent

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Dietary supplement: Placebo; Rice Flour
Active Comparator: Qualia NAD⁺ version 1	Dietary supplement: Qualia NAD⁺ version 1; Qualia NAD+ version 1 manufactured by Qualia Life Sciences
Active Comparator: Qualia NAD⁺ version 2	Dietary supplement: Qualia NAD⁺ version 2; Qualia NAD+ version 2 manufactured by Qualia Life Sciences

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Between-group change in intracellular NAD⁺ levels	To assess between-group differences in the change in intracellular NAD⁺ levels from baseline to Week 4 following supplementation with Qualia NAD version 1, Qualia NAD version 2, or placebo.	28 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Aging-Related Symptoms (AMFS scores)	To evaluate within-group and between-group differences in the change in Aging Male/Female Symptom (AMFS) total and sub-scale scores.	4 weeks
RAND SF-36 Scale Scores	To assess within-group and between-group differences in RAND SF-36 domain scores.	4 weeks
Side effect profile as measured by a custom Safety and Tolerability survey	To evaluate side effect profiles using a custom Safety and Tolerability survey.	Week 1, 2, 3, and 4
Within-group differences in the change in intracellular NAD⁺ levels	To assess within-group differences in the change in intracellular NAD⁺ levels	4 weeks

Collaborators and Investigators

• Sponsor: Qualia Life Sciences

Study record dates

Study Major Dates

• Study Start (Estimated): October 13, 2025
• Primary Completion (Estimated): November 30, 2025
• Study Completion (Estimated): December 15, 2025

Study Registration Dates

• First Submitted: August 13, 2025
• First Submitted That Met QC Criteria: August 13, 2025
• First Posted (Actual): August 20, 2025

Study Record Updates

• Last Update Posted (Actual): August 20, 2025
• Last Update Submitted That Met QC Criteria: August 13, 2025
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Keywords: NAD; NAD Supplementation
• Other Study ID Numbers: QLS-014

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No